141 related articles for article (PubMed ID: 28164611)
21. Osteoactivin regulates head and neck squamous cell carcinoma invasion by modulating matrix metalloproteases.
Arosarena OA; Barr EW; Thorpe R; Yankey H; Tarr JT; Safadi FF
J Cell Physiol; 2018 Jan; 233(1):409-421. PubMed ID: 28295306
[TBL] [Abstract][Full Text] [Related]
22. Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma--tissue immunoreactivity predicts aggressive clinical course.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Mod Pathol; 2006 Feb; 19(2):208-17. PubMed ID: 16424893
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
24. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck.
O-Charoenrat P; Rhys-Evans PH; Eccles SA
Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):813-20. PubMed ID: 11448356
[TBL] [Abstract][Full Text] [Related]
25. Prognostic role of MMP-9 expression in head and neck carcinoma patients treated with radiotherapy or chemoradiotherapy.
Virós D; Camacho M; Zarraonandia I; García J; Quer M; Vila L; León X
Oral Oncol; 2013 Apr; 49(4):322-5. PubMed ID: 23122824
[TBL] [Abstract][Full Text] [Related]
26. [Matrix metalloproteinase 2 and 9 as the factor of head and neck tumor metastasis].
Kondakova IV; Klisho EV; savenkova OV; Kakurina GV; Choĭnzonov EL; Shishkin DA; Mukhamedov MP
Biomed Khim; 2008; 54(5):555-60. PubMed ID: 19105397
[TBL] [Abstract][Full Text] [Related]
27. Serum samples should not be used to assess circulating matrix metalloproteinase-9 levels as a prognostic marker of disease.
Tanus-Santos JE; Gerlach RF
Int J Cancer; 2006 Feb; 118(3):789; author reply 790. PubMed ID: 16094623
[No Abstract] [Full Text] [Related]
28. Serum levels of MMP9 and MMP2 in patients with oral squamous cell carcinoma.
Lotfi A; Mohammadi G; Tavassoli A; Mousaviagdas M; Chavoshi H; Saniee L
Asian Pac J Cancer Prev; 2015; 16(4):1327-30. PubMed ID: 25743793
[TBL] [Abstract][Full Text] [Related]
29. Expression of matrix metalloproteinase-12 is correlated with extracapsular spread of tumor from nodes with metastasis in head and neck squamous cell carcinoma.
Kim JM; Kim HJ; Koo BS; Rha KS; Yoon YH
Eur Arch Otorhinolaryngol; 2013 Mar; 270(3):1137-42. PubMed ID: 22907031
[TBL] [Abstract][Full Text] [Related]
30. Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas.
Görögh T; Beier UH; Bäumken J; Meyer JE; Hoffmann M; Gottschlich S; Maune S
Head Neck; 2006 Jan; 28(1):31-9. PubMed ID: 16265652
[TBL] [Abstract][Full Text] [Related]
31. Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma.
Hashimoto T; Uchida K; Okayama N; Imate Y; Suehiro Y; Hamanaka Y; Ueyama Y; Shinozaki F; Yamashita H; Hinoda Y
Cancer Lett; 2004 Jul; 211(1):19-24. PubMed ID: 15194213
[TBL] [Abstract][Full Text] [Related]
32. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
33. Serum Level of Matrix Metalloproteinase-2 and -9 in Patients with Laryngeal Squamous Cell Carcinoma and Clinical Significance.
Lotfi A; Mohammadi G; Saniee L; Mousaviagdas M; Chavoshi H; Tavassoli A
Asian Pac J Cancer Prev; 2015; 16(15):6749-51. PubMed ID: 26434905
[TBL] [Abstract][Full Text] [Related]
34. Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness.
Culhaci N; Metin K; Copcu E; Dikicioglu E
BMC Cancer; 2004 Aug; 4():42. PubMed ID: 15291964
[TBL] [Abstract][Full Text] [Related]
35. Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma.
Charous SJ; Stricklin GP; Nanney LB; Netterville JL; Burkey BB
Ann Otol Rhinol Laryngol; 1997 Apr; 106(4):271-8. PubMed ID: 9109715
[TBL] [Abstract][Full Text] [Related]
36. Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma.
Hagiwara S; Sasaki E; Hasegawa Y; Suzuki H; Nishikawa D; Beppu S; Terada H; Sawabe M; Takahashi M; Hanai N
Cancer Med; 2021 Feb; 10(4):1335-1346. PubMed ID: 33565282
[TBL] [Abstract][Full Text] [Related]
37. Alpha-mangostin suppresses MMP-2 and MMP-9 expression in head and neck squamous carcinoma cells.
Kaomongkolgit R
Odontology; 2013 Jul; 101(2):227-32. PubMed ID: 22832848
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
Aderhold C; Umbreit C; Faber A; Birk R; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2014 Sep; 34(9):4929-37. PubMed ID: 25202075
[TBL] [Abstract][Full Text] [Related]
39. Squamous cell carcinoma antigen as a prognostic marker and its correlation with clinicopathological features in head and neck squamous cell carcinoma: Systematic review and meta-analysis.
Travassos DC; Fernandes D; Massucato EMS; Navarro CM; Bufalino A
J Oral Pathol Med; 2018 Jan; 47(1):3-10. PubMed ID: 28600896
[TBL] [Abstract][Full Text] [Related]
40. Arterial spin labeling perfusion-weighted MR imaging: correlation of tumor blood flow with pathological degree of tumor differentiation, clinical stage and nodal metastasis of head and neck squamous cell carcinoma.
Abdel Razek AAK; Nada N
Eur Arch Otorhinolaryngol; 2018 May; 275(5):1301-1307. PubMed ID: 29582174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
